Menu
GWAS Study

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N et al.

28025584 PubMed ID
GWAS Study Type
8755 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

DS
da Silva Filho MI
FA
Försti A
WN
Weinhold N
MI
Meziane I
CC
Campo C
HS
Huhn S
NJ
Nickel J
HP
Hoffmann P
NM
Nöthen MM
JK
Jöckel KH
LS
Landi S
MJ
Mitchell JS
JD
Johnson D
MG
Morgan GJ
HR
Houlston R
GH
Goldschmidt H
JA
Jauch A
MP
Milani P
MG
Merlini G
RD
Rowcieno D
HP
Hawkins P
HU
Hegenbart U
PG
Palladini G
WA
Wechalekar A
SS
Schönland SO
HK
Hemminki K
Chapter II

Abstract

Summary of the research findings

Immunoglobulin light chain (AL) amyloidosis is characterized by tissue deposition of amyloid fibers derived from immunoglobulin light chain. AL amyloidosis and multiple myeloma (MM) originate from monoclonal gammopathy of undetermined significance. We wanted to characterize germline susceptibility to AL amyloidosis using a genome-wide association study (GWAS) on 1229 AL amyloidosis patients from Germany, UK and Italy, and 7526 healthy local controls. For comparison with MM, recent GWAS data on 3790 cases were used. For AL amyloidosis, single nucleotide polymorphisms (SNPs) at 10 loci showed evidence of an association at P<10-5 with homogeneity of results from the 3 sample sets; some of these were previously documented to influence MM risk, including the SNP at the IRF4 binding site. In AL amyloidosis, rs9344 at the splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, P=7.80 × 10-11; the SNP was only marginally significant in MM. SNP rs79419269 close to gene SMARCD3 involved in chromatin remodeling was also significant (P=5.2 × 10-8). These data provide evidence for common genetic susceptibility to AL amyloidosis and MM. Cyclin D1 is a more prominent driver in AL amyloidosis than in MM, but the links to aggregation of light chains need to be demonstrated.

1,229 cases, 7,526 controls

Chapter III

Study Statistics

Key metrics and study information

8755
Total Participants
GWAS
Study Type
No
Replicated
Italy, Germany, U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.